Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 amp||stomach cancer||sensitive||AZD4547||Preclinical||Actionable||In a preclinical study, AZD4547 inhibited FGFR signaling, and decreased proliferation and induced cell-cycle arrest in gastric cancer cells with amplification and over expression of FGFR2 in culture (PMID: 22869148).||22869148|
|FGFR2 amp||stomach cancer||sensitive||AZD4547||Phase II||Actionable||In a Phase II clinical trial, treatment with AZD4547 resulted in a 33% (3/9) response rate in patients with FGFR2-amplified gastroesophageal cancer, and high-level amplification was associated with clinical response (PMID: 27179038).||27179038|
|FGFR2 amp||stomach cancer||sensitive||AZD4547||Preclinical - Cell culture||Actionable||In a preclinical study, AZD4547 inhibited growth of a gastric cancer cell line harboring FGFR2 amplification in culture (PMID: 30045926).||30045926|
|PubMed Id||Reference Title||Details|
|(22869148)||Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.||Full reference...|
|(27179038)||High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.||Full reference...|
|(30045926)||Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.||Full reference...|